리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 07월
페이지 정보:영문 370 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 외용약 CDMO 시장은 2030년까지 797억 달러에 도달
2024년에 449억 달러로 추정되는 세계의 외용약 CDMO 시장은 2024-2030년에 CAGR 10.0%로 성장하며, 2030년에는 797억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 반고형 제제는 CAGR 8.4%를 기록하며, 분석 기간 종료시에는 308억 달러에 달할 것으로 예측됩니다. 액체 제제 의약품 부문의 성장률은 분석 기간 중 CAGR 12.1%로 추정됩니다.
미국 시장은 122억 달러로 추정, 중국은 CAGR 13.4%로 성장 예측
미국의 외용약 CDMO 시장은 2024년에 122억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 160억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 13.4%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 7.4%와 8.7%로 예측됩니다. 유럽에서는 독일이 CAGR 7.8%로 성장할 것으로 예측됩니다.
외용약 CDMO 시장 동향과 촉진요인 정리
CDMO는 의약품 개발 환경에 어떤 혁명을 가져오고 있는가?
CDMO(의약품 개발 및 제조 수탁기관)는 제제 개발부터 상업적 규모의 생산까지 엔드-투-엔드 서비스를 제공함으로써 성장하는 외용제 시장에서 중요한 역할을 하고 있습니다. 피부과, 통증 관리, 경피약물전달에 대한 외용제 수요 증가는 젤, 크림, 로션, 연고, 패치 등 외용제 전문 CDMO의 성장을 가속하고 있습니다. 생물제제 및 새로운 약물전달 기술의 부상으로 시장 잠재력이 더욱 커지고 있으며, 제약사들은 비용 절감과 시장 출시 시간 단축을 위해 CDMO에 연구개발 및 제조를 위탁하고 있습니다. 그러나 복잡한 규제, 공급망 문제, 특수 외용제제의 높은 비용 등은 여전히 큰 걸림돌로 작용하고 있습니다. 제약기업이 효율성과 유연성을 우선시하는 가운데, CDMO는 외용제 분야에서 어떻게 혁신을 계속 추진할 수 있는가?
어떤 기술 혁신이 외용제 CDMO의 능력을 발전시키고 있는가?
마이크로인캡슐레이션 및 나노입자 기반 약물전달의 발전으로 외용제의 효능과 안정성이 향상되고 있습니다. AI를 활용한 예측 모델링은 제제 개발을 최적화하고 초기 단계의 시험에 소요되는 시간과 비용을 절감하고 있습니다. 경피용 마이크로니들 패치는 비침습적 약물전달의 대안으로 부상하고 있으며, CDMO의 능력을 기존의 크림이나 연고 이상으로 확장하고 있습니다. 연속 처리 및 실시간 품질관리 분석을 포함한 스마트 제조 기술은 생산 효율을 높이고 있습니다. 또한 바이오의약품의 발전으로 펩티드와 단백질을 외용제에 접목할 수 있게 되면서 만성 피부 질환과 통증 관리에 대한 치료 옵션이 확대되고 있습니다.
외용제 CDMO에 대한 수요가 증가하는 이유는 무엇인가?
피부 질환의 유병률 증가, 비침습적 약물 투여에 대한 선호도 증가, 경피 약물전달 시스템에 대한 수요 증가로 전문 CDMO의 필요성이 높아지고 있습니다. 제약회사들은 인프라 비용을 절감하고 엄격한 규제 요건을 극복하기 위해 개발 및 제조 아웃소싱을 점점 더 많이 추진하고 있습니다. 맞춤형 의료와 맞춤형 국소 치료의 출현은 유연한 CDMO 파트너십에 대한 수요를 더욱 촉진하고 있습니다.
외용제 CDMO 시장의 성장을 가속하는 요인은 무엇인가?
약물전달 기술의 발전, 의약품 제조 아웃소싱 증가, 피부과 치료 및 경피 요법에 대한 수요 증가, 바이오의약품의 CDMO 역량 확대가 시장 성장을 촉진하고 있습니다. 전 세계 제약업계가 수탁제조을 계속 받아들이고 있는 가운데, 외용제 전문 CDMO는 제약회사에 혁신적이고 비용 효율적인 솔루션을 제공함으로써 큰 성장을 이룰 수 있을 것입니다.
부문
제품 유형(반고형 제제, 액체 제제, 고형 제제, 경피 흡수형 제제), 서비스 유형(수탁개발, 수탁제조), 최종사용자(제약회사, 바이오 제약회사, 기타)
조사 대상 기업의 예
AbbVie Contract Manufacturing
Acino
Adare Pharma Solutions
Alcami Corporation
Ascendia Pharmaceuticals
Aurobindo Pharma
Avara Pharmaceutical Services
Avid Bioservices
Bora Pharmaceuticals
Cambrex Corporation
Catalent, Inc.
CordenPharma
DPT Laboratories Ltd.
Famar
Jubilant HollisterStier
Kindeva Drug Delivery
Lubrizol Life Science
MedPharm Ltd.
Patheon(Thermo Fisher Scientific)
PCI Pharma Services
Pierre Fabre Group
Piramal Pharma Solutions
AI 통합
당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Topical Drugs CDMO Market to Reach US$79.7 Billion by 2030
The global market for Topical Drugs CDMO estimated at US$44.9 Billion in the year 2024, is expected to reach US$79.7 Billion by 2030, growing at a CAGR of 10.0% over the analysis period 2024-2030. Semi-solid Formulations, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$30.8 Billion by the end of the analysis period. Growth in the Liquid Formulations Drugs segment is estimated at 12.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$12.2 Billion While China is Forecast to Grow at 13.4% CAGR
The Topical Drugs CDMO market in the U.S. is estimated at US$12.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.0 Billion by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.4% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.
How Are CDMOs Revolutionizing the Topical Drug Development Landscape?
Contract Development and Manufacturing Organizations (CDMOs) are playing a crucial role in the growing topical drug market by offering end-to-end services, from formulation development to commercial-scale production. The increasing demand for topical drugs in dermatology, pain management, and transdermal drug delivery is fueling the expansion of CDMOs specializing in gels, creams, lotions, ointments, and patches. The rise of biologics and novel drug delivery technologies is further enhancing market potential, with pharmaceutical companies outsourcing R&D and manufacturing to CDMOs to reduce costs and accelerate time-to-market. However, regulatory complexities, supply chain challenges, and the high costs of specialized topical formulations remain significant hurdles. As pharmaceutical firms prioritize efficiency and flexibility, how will CDMOs continue to drive innovation in the topical drug sector?
What Technological Innovations Are Advancing Topical Drug CDMO Capabilities?
Advancements in microencapsulation and nanoparticle-based drug delivery are improving the efficacy and stability of topical formulations. AI-driven predictive modeling is optimizing formulation development, reducing time and costs in early-stage trials. Transdermal microneedle patches are emerging as a non-invasive alternative for drug delivery, expanding CDMO capabilities beyond traditional creams and ointments. Smart manufacturing technologies, including continuous processing and real-time quality control analytics, are enhancing production efficiency. Additionally, biopharmaceutical advancements are allowing the incorporation of peptides and proteins into topical therapies, expanding treatment options for chronic skin diseases and pain management.
Why Is the Demand for Topical Drug CDMOs Increasing?
The rising prevalence of dermatological conditions, increasing preference for non-invasive drug administration, and growing demand for transdermal drug delivery systems are driving the need for specialized CDMOs. Pharmaceutical companies are increasingly outsourcing development and manufacturing to reduce infrastructure costs and navigate stringent regulatory requirements. The emergence of personalized medicine and customized topical therapies is further fueling demand for flexible CDMO partnerships.
What Factors Are Driving the Growth of the Topical Drug CDMO Market?
The market is growing due to advancements in drug delivery technologies, increasing outsourcing of pharmaceutical manufacturing, rising demand for dermatological and transdermal therapies, and expanding CDMO capabilities in biopharmaceutical formulations. As the global pharmaceutical landscape continues to embrace contract manufacturing, CDMOs specializing in topical drugs are poised for significant growth, offering innovative, cost-effective solutions for pharmaceutical companies.
SCOPE OF STUDY:
The report analyzes the Topical Drugs CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product Type (Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations, Transdermal Products); Service Type (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 37 Featured) -
AbbVie Contract Manufacturing
Acino
Adare Pharma Solutions
Alcami Corporation
Ascendia Pharmaceuticals
Aurobindo Pharma
Avara Pharmaceutical Services
Avid Bioservices
Bora Pharmaceuticals
Cambrex Corporation
Catalent, Inc.
CordenPharma
DPT Laboratories Ltd.
Famar
Jubilant HollisterStier
Kindeva Drug Delivery
Lubrizol Life Science
MedPharm Ltd.
Patheon (Thermo Fisher Scientific)
PCI Pharma Services
Pierre Fabre Group
Piramal Pharma Solutions
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Topical Drugs CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Demand for Dermatology and Pain Relief Products Fuels Topical Drug Outsourcing
Growth in Generic and OTC Formulations Boosts Contract Manufacturing Opportunities
Rising Complexity of Topical Formulations Drives Need for Specialized CDMO Expertise
Focus on Sustained Release and Permeation-Enhanced Technologies Supports R&D Partnerships
Regulatory Pressure on In-House Compliance Drives Pharma to Outsource Topical Pipelines
Customization of Creams, Gels, Ointments, and Sprays Supports CDMO Differentiation
CDMOs Expanding Value-Added Services Including Packaging and Regulatory Filing
Growing Clinical Pipeline in Skin Diseases and Wound Care Accelerates CDMO Demand
Preference for Site-Specific Drug Delivery Encourages Innovation in Topical Routes
Global Pharma Shift to Virtual Models Enhances CDMO Role in Early-Stage Development
Emerging Markets Offer Cost-Effective Scale-Up Capabilities for Topical Drug Projects
Increasing Demand for Cleanroom Compliance and GMP Facilities Boosts Strategic CDMO Contracts
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Topical Drugs CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Topical Drugs CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Topical Drugs CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Topical Drugs CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Semi-solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Semi-solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Semi-solid Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Liquid Formulations Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Liquid Formulations Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Liquid Formulations Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Solid Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Solid Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Transdermal Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Transdermal Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Transdermal Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Contract Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Contract Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Contract Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 32: USA Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: USA 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: USA Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: USA 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: USA 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
CANADA
TABLE 41: Canada Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Canada 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 44: Canada Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Canada 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Canada 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
JAPAN
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 50: Japan Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Japan Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Japan 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 53: Japan Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Japan 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Japan 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
CHINA
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 59: China Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: China Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: China 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: China Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: China 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 65: China Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: China 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
EUROPE
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 68: Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Topical Drugs CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Europe 15-Year Perspective for Topical Drugs CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 71: Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Europe 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Europe 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
FRANCE
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 80: France Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: France Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: France 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 83: France Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: France Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: France 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: France 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
GERMANY
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 89: Germany Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Germany Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Germany 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Germany 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 95: Germany Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Germany 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
ITALY
TABLE 98: Italy Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Italy Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Italy 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 101: Italy Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Italy 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Italy 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
UNITED KINGDOM
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 107: UK Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: UK Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: UK 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 110: UK Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: UK Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: UK 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 113: UK Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: UK 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
SPAIN
TABLE 116: Spain Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Spain Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: Spain 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 119: Spain Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Spain Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: Spain 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 122: Spain Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Spain 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
RUSSIA
TABLE 125: Russia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Russia Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Russia 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 128: Russia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Russia Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Russia 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 131: Russia Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Russia 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Europe Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Rest of Europe 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Rest of Europe Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Rest of Europe 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Rest of Europe 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Topical Drugs CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Asia-Pacific Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
AUSTRALIA
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 155: Australia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Australia Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Australia 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 158: Australia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Australia Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Australia 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 161: Australia Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Australia 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
INDIA
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 164: India Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: India Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: India 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 167: India Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: India Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: India 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 170: India Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: India Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: India 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 173: South Korea Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: South Korea Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: South Korea 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 176: South Korea Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: South Korea Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: South Korea 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 179: South Korea Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: South Korea 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of Asia-Pacific Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Asia-Pacific Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
LATIN AMERICA
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 191: Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 192: Latin America Historic Review for Topical Drugs CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Latin America 15-Year Perspective for Topical Drugs CDMO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 194: Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Latin America Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Latin America 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 197: Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: Latin America 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: Latin America 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 203: Argentina Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Argentina Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Argentina 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 206: Argentina Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Argentina Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Argentina 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 209: Argentina Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Argentina 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
BRAZIL
TABLE 212: Brazil Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Brazil Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Brazil 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 215: Brazil Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Brazil Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 217: Brazil 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 218: Brazil Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 220: Brazil 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
MEXICO
TABLE 221: Mexico Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Mexico Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 223: Mexico 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 224: Mexico Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Mexico Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 226: Mexico 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 227: Mexico Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 229: Mexico 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Rest of Latin America Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 232: Rest of Latin America 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Rest of Latin America Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 235: Rest of Latin America 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 238: Rest of Latin America 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
MIDDLE EAST
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 239: Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 240: Middle East Historic Review for Topical Drugs CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 241: Middle East 15-Year Perspective for Topical Drugs CDMO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 242: Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Middle East Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 244: Middle East 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 245: Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 247: Middle East 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 250: Middle East 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
IRAN
TABLE 251: Iran Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Iran Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 253: Iran 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 254: Iran Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Iran Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 256: Iran 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 257: Iran Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 259: Iran 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
ISRAEL
TABLE 260: Israel Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Israel Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 262: Israel 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 263: Israel Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Israel Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 265: Israel 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 266: Israel Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 268: Israel 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Saudi Arabia Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 271: Saudi Arabia 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Saudi Arabia Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 274: Saudi Arabia 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 277: Saudi Arabia 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 278: UAE Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: UAE Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 280: UAE 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 281: UAE Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: UAE Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 283: UAE 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 284: UAE Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 286: UAE 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: Rest of Middle East Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 289: Rest of Middle East 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: Rest of Middle East Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 292: Rest of Middle East 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 295: Rest of Middle East 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030
AFRICA
Topical Drugs CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 296: Africa Recent Past, Current & Future Analysis for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Africa Historic Review for Topical Drugs CDMO by Product Type - Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 298: Africa 15-Year Perspective for Topical Drugs CDMO by Product Type - Percentage Breakdown of Value Sales for Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations and Transdermal Products for the Years 2015, 2025 & 2030
TABLE 299: Africa Recent Past, Current & Future Analysis for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Africa Historic Review for Topical Drugs CDMO by Service Type - Contract Development and Contract Manufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 301: Africa 15-Year Perspective for Topical Drugs CDMO by Service Type - Percentage Breakdown of Value Sales for Contract Development and Contract Manufacturing for the Years 2015, 2025 & 2030
TABLE 302: Africa Recent Past, Current & Future Analysis for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Topical Drugs CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 304: Africa 15-Year Perspective for Topical Drugs CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Others for the Years 2015, 2025 & 2030